 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
11 News |  |
- INO-4201 / Inovio, Ervebo (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of Ebola Virus Zaire) / Merck (MSD)
Safety and immunogenicity of the DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSV-ZEBOV-primed volunteers: an investigator-initiated phase Ib, placebo-controlled, randomised clinical trial (Boost-EBOV) (Hall K) - Mar 13, 2023 - Abstract #ECCMID2023ECCMID_5417;
- || INO-4201 / Inovio
Trial completion, Trial primary completion date: Boost-EBOV: INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees (clinicaltrials.gov) - May 23, 2022
P1, N=46, Completed, Sponsor: University of Geneva, Switzerland
Not yet recruiting --> Completed | Trial primary completion date: Apr 2022 --> Jan 2022
- || INO-4201 / Inovio
New P1 trial: Boost-EBOV: INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees (clinicaltrials.gov) - May 27, 2021
P1, N=50, Not yet recruiting, Sponsor: University of Geneva, Switzerland
- |||||| INO-4201 / Inovio
P1 data: Inovio pharmaceuticals candidate INO-4201 completed Phase 1 on Ebola.These vaccine companies need support to get safe and effective vaccines out for these horrible diseases! (Twitter) - Feb 7, 2021
- || INO-4201 / Inovio
Clinical, Journal: Intradermal SynCon® Ebola GP DNA Vaccine is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. (Pubmed Central) - Feb 24, 2020
P1
Not yet recruiting --> Completed | Trial primary completion date: Apr 2022 --> Jan 2022 Intradermal delivery of INO-4201 was well-tolerated and resulted in 100% seroreactivity after two doses and elicited interferon-γ T cell responses in over 70% of subjects, providing a new approach for EBOV prevention in diverse populations.
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
Trial completion: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Aug 2, 2018
P1, N=240, Completed, Sponsor: Inovio Pharmaceuticals
Intradermal delivery of INO-4201 was well-tolerated and resulted in 100% seroreactivity after two doses and elicited interferon-γ T cell responses in over 70% of subjects, providing a new approach for EBOV prevention in diverse populations. Active, not recruiting --> Completed
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
Enrollment closed: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Apr 12, 2017
P1, N=240, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
Enrollment open, Enrollment change, Trial primary completion date: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Mar 14, 2017
P1, N=240, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | N=200 --> 240 | Trial primary completion date: Dec 2017 --> May 2018
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
Enrollment closed: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Nov 15, 2016
P1, N=200, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Recruiting | N=200 --> 240 | Trial primary completion date: Dec 2017 --> May 2018 Recruiting --> Active, not recruiting
- ||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
Enrollment open, Enrollment change, Trial primary completion date: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Aug 24, 2016
P1, N=200, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | N=75 --> 200 | Trial primary completion date: Dec 2016 --> Dec 2017
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
Enrollment closed: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Oct 19, 2015
P1, N=75, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Recruiting | N=75 --> 200 | Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- ||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
New P1 trial: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Jun 6, 2015
P1, N=75, Recruiting, Sponsor: Inovio Pharmaceuticals